Healthcare
Syra Health Corp. Class A Common Stock(SYRA)
Live Price
Offline$0.45
-18.18% today
1Y Change
+454.46%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $10.00M
- Revenue Growth
- -9.5%
- EPS Growth
- +85.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Syra Health Corp. Class A Common Stock (SYRA) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.45 and up 454.5% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -9.5%, EPS growth of +85.5%, a dividend yield of 0.0%. What stands out right now is revenue -9.5%, EPS +85.5%, free cash flow +84.8% with operating margin -12.5% and ROIC -40.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SYRA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-9.5% vs +7.6% peer median
Operating Margin
Below sector median
-12.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -9.5% and EPS is at +85.5%, with operating margin around -12.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +27.4% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +10.0% | +0.0% | +1.8% |
2026 Mar 12, 2026 | +85.7% | +0.0% | +62.9% | +216.2% |
2025 Nov 12, 2025 | โ | +4.5% | +19.4% | +6.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYRA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SYRA Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SYRA and SPY.
Company Overview
Syra Health Corp. Class A Common Stock
Other OTC
Syra Health Corp., a healthcare services company, provides health education, population health management, behavioral and mental health, healthcare workforce, and digital health services in the United States. It offers health education services, including medical communications, patient education, and healthcare training; and population health management services, such as analytics as a service, epidemiology, and health equity analytics solutions. The company also engages in developing Syrenity, an on-demand telehealth platform for mental health services. In addition, the company provides healthcare staffing solutions; and digital health solutions comprising digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. Syra Health Corp. was incorporated in 2020 and is headquartered in Carmel, Indiana.
- Leadership
- Gregory R. Alexander
- IPO Date
- Sep 29, 2023
- Employees
- 57
- Street Address
- 1119 Keystone Way North
- Mailing
- Carmel, DE, 46032
- Region
- Carmel, DE, US
- Reporting Currency
- USD
- Investor Line
- 463-345-8950
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.8
- Price/Book
- 2.7
Growth
- Revenue
- -9.5%
- EPS
- +85.5%
- Free Cash Flow
- +84.8%
Profitability
- Gross Margin
- 29.8%
- Operating Margin
- -12.5%
- Net Margin
- -12.4%
- ROE
- -39.1%
- ROIC
- -40.3%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 4.06
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.